(01 May 2020) Telmisartan- treating COVID-19 patients prior to development of ARDS
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19
https://doi.org/10.1002/ddr.21679
High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self‐powered cascade, leading eventually to ARDS. Telmisartan is an angiotensin II receptor blocker used in the therapy. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open‐label randomized phase II clinical trial for the evaluation of telmisartan in COVID‐19 patients (
).